Following subcutaneous injection into mice, tumor formation was impeded in UBE2L6-overexpressing 28:B4:F3 recipient mice compared to controls (Fig. 3O), although differences in tumor volume were not statistically significant at 15 weeks (Fig. 3P). This evidence concerns the gene UBE2L6 and neoplasm.